MedMatrix Rx
Daily 340B Morning Briefing
Several major developments are shaping the 340B landscape. The NASP has submitted comments on CMS’ proposed 340B payment changes. These comments address potential impacts on specialty pharmacy services. Meanwhile, a Milwaukee hospital has filed a lawsuit against CVS Health, alleging $18 million in 340B diversion. Additionally, healthcare groups are urging CMS to reconsider key provisions in the 2027 outpatient rule. These actions reflect ongoing tensions and adjustments in the 340B program, impacting reimbursement and compliance strategies.
EXECUTIVE SUMMARY
01
NASP comments on CMS’ proposed 340B payment changes.
NASP submitted comments to CMS on the CY 2027 HOPPS proposed rule, focusing on reimbursement changes and implications for specialty pharmacy.
NASP submitted comments to CMS on the CY 2027 HOPPS proposed rule, focusing on reimbursement changes and implications for specialty pharmacy.
02
Milwaukee hospital sues CVS over alleged 340B diversion.
Froedtert Memorial Lutheran Hospital filed a lawsuit against CVS Health, alleging $18 million in diverted 340B savings from 2020 to 2025.
Froedtert Memorial Lutheran Hospital filed a lawsuit against CVS Health, alleging $18 million in diverted 340B savings from 2020 to 2025.
Source: Becker’s Hospital Review
03
Healthcare groups urge CMS to revise 2027 outpatient rule.
AHA, AAMC, and AMGA submitted comments urging CMS to withdraw or modify key provisions of the 2027 outpatient proposed rule.
AHA, AAMC, and AMGA submitted comments urging CMS to withdraw or modify key provisions of the 2027 outpatient proposed rule.
Source: Becker’s Hospital Review
04
Court sides with drugmakers in 340B dispute, decertifies clinics.
A D.C. federal judge decertified 11 clinics from the 340B program, siding with drugmakers on statutory requirements.
A D.C. federal judge decertified 11 clinics from the 340B program, siding with drugmakers on statutory requirements.
Source: Becker’s Hospital Review
05
AHA warns CMS on 340B repayment acceleration.
AHA cautioned CMS against finalizing a proposal that would increase the repayment rate for 340B overpayments sixfold.
AHA cautioned CMS against finalizing a proposal that would increase the repayment rate for 340B overpayments sixfold.
Source: Becker’s Hospital Review
06
340B rebate model pilot to launch in 2027.
HRSA’s revised 340B rebate model pilot program will start on January 1, 2027, focusing on MFP drugs from 2026-2027.
HRSA’s revised 340B rebate model pilot program will start on January 1, 2027, focusing on MFP drugs from 2026-2027.
Source: Drug Channels (Adam Fein)
07
Federal court updates in 340B legal battles.
Multiple court cases continue to shape the 340B landscape, with ongoing disputes over contract pharmacy access and eligibility.
Multiple court cases continue to shape the 340B landscape, with ongoing disputes over contract pharmacy access and eligibility.
Source: Becker’s Hospital Review
08
Site-neutral payment pressures health systems.
Health systems like Valley Health are adjusting outpatient strategies due to site-neutral payment considerations and financial pressures.
Health systems like Valley Health are adjusting outpatient strategies due to site-neutral payment considerations and financial pressures.
Source: Becker’s Hospital Review
09
AAMC, AHA push for 340B provision changes.
AAMC and AHA submitted letters targeting CMS’s Medicare Drug Price Negotiation Program rule and Sen. Cassidy’s 340B draft.
AAMC and AHA submitted letters targeting CMS’s Medicare Drug Price Negotiation Program rule and Sen. Cassidy’s 340B draft.
Source: Becker’s Hospital Review
10
Medicaid, ACA cuts impact health system strategies.
Hospital CFOs are preparing for the effects of HR 1, which includes Medicaid work requirements and provider tax restrictions.
Hospital CFOs are preparing for the effects of HR 1, which includes Medicaid work requirements and provider tax restrictions.
Source: Becker’s Hospital Review
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The ongoing 340B legal battles and policy changes reveal the complex dynamics between drug manufacturers, healthcare providers, and regulatory bodies. These developments could significantly impact reimbursement models, compliance requirements, and the operational strategies of covered entities. The focus on site-neutral payments and the potential acceleration of 340B repayment obligations show the financial pressures facing healthcare systems. Stakeholders must address these challenges to maintain access to affordable medications for vulnerable populations.
Emerging risks.
- 340B program changes may lead to reduced reimbursement rates for covered entities.
- Legal disputes could result in unfavorable rulings for healthcare providers, affecting program participation.
- Acceleration of 340B repayment obligations could strain hospital finances.
- Site-neutral payment policies may limit expansion of outpatient services.
- Medicaid and ACA cuts could reduce funding for vulnerable populations.
Emerging opportunities.
- Engaging in advocacy efforts can influence CMS rulemaking processes.
- Exploring alternative payment models may offer financial stability.
- Specialty pharmacy services can improve patient access and care.
- Participating in pilot programs like the 340B rebate model can provide insights into new reimbursement strategies.
- Collaboration with industry groups can strengthen policy positions.
Key actions for providers.
- Review and adjust compliance strategies to align with new 340B requirements.
- Engage with CMS during comment periods to influence policy outcomes.
- Monitor legal developments and prepare for potential impacts on 340B participation.
- Evaluate financial strategies to mitigate risks from reimbursement changes.
- Strengthen partnerships with advocacy groups to support policy initiatives.
TOP STORIES
NASP comments on CMS’ proposed 340B changes.
NASP — National Association of Specialty Pharmacy · September 1, 2026
- NASP submitted comments on CMS’ CY 2027 HOPPS proposed rule.
- Focus on Medicare reimbursement changes and specialty pharmacy implications.
- Comments address operational and compliance considerations.
Milwaukee hospital sues CVS over 340B diversion.
Becker’s Hospital Review · August 31, 2026
- Froedtert Memorial Lutheran Hospital alleges $18 million in 340B savings diverted.
- Lawsuit filed against CVS Health and subsidiaries.
- Claims involve adjudication of 340B-eligible specialty drug claims.
Healthcare groups urge CMS to revise 2027 rule.
Becker’s Hospital Review · August 31, 2026
- AHA, AAMC, and AMGA submitted comments to CMS.
- Groups oppose 340B payment cuts and site-neutral payment expansion.
- Concerns over prior authorization requirements.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
AHA warns CMS on 340B repayment acceleration.
Becker’s Hospital Review · August 26, 2026
- AHA opposes CMS proposal to increase 340B repayment rate.
- Proposal would raise repayment from 0.5% to 3%.
- AHA warns of financial strain on hospitals.
340B rebate model pilot to launch in 2027.
Drug Channels (Adam Fein) · August 25, 2026
- HRSA’s revised 340B rebate model pilot starts January 1, 2027.
- Focus on MFP drugs from 2026-2027.
- Pilot addresses nonduplication requirement with 340B ceiling price.
Site-neutral payment pressures health systems.
Becker’s Hospital Review · August 28, 2026
- Health systems face financial pressures from site-neutral payment policies.
- Valley Health adjusts outpatient strategies to mitigate impact.
- Site-neutral payments influence investment decisions.
STATE DEVELOPMENTS
Washington — State Health Care Authority Updates 340B Program Information
Washington State Health Care Authority · September 10, 2026
- Washington State Health Care Authority provides detailed information on the federal 340B Drug Pricing Program.
- Clarifies overlap with the Medicaid Drug Rebate Program (MDRP) and guidelines to avoid duplicate discounts.
- Offers guidance on eligibility, requirements, and participation in the 340B program.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| E.D. Wis. | Froedtert Memorial Lutheran Hospital Inc v. CVS Health Corporation [source] | August 20, 2026 |
| D.D.C. | COREWELL HEALTH WILLIAM BEAUMONT UNIVERSITY HOSPITAL v. KENNEDY [source] | September 3, 2026 |
| M.D. Fla. | The Elevance Health Companies, Inc. v. Senderra Rx Partners, LLC [source] | September 4, 2026 |
| D.D.C. | ABBVIE INC. v. KENNEDY, 1:26-cv-1190-RDM, filed 2026-08-24. [source] | August 24, 2026 |
SOCIAL MEDIA & STAKEHOLDER SENTIMENT
Identified and summarized recent stakeholder and social commentary on the 340B Drug Pricing Program from the past 90 days, including reactions, statements, op-eds, and advocacy positions from various organizations and platforms.
340B Health Responds to Senator Cassidy’s 340B Discussion Draft
340B Health News Releases · June 25, 2026
- Main theme: 340B Health responds to proposed changes in the 340B program by Senator Cassidy.
- Stakeholder sentiment: 340B Health expresses concern over proposed changes that could make it more difficult for safety-net hospitals to provide essential care.
- Potential implications: Potential challenges for hospitals in delivering care to underserved communities.
- Credibility: 340B Health is a national trade association representing over 1,600 hospitals participating in 340B.
WHAT TO WATCH NEXT
- CMS decision on 2027 outpatient rule revisions following stakeholder comments. [source]
- Launch of HRSA’s 340B rebate model pilot program on January 1, 2027. [source]
- Potential impacts of site-neutral payment policies on outpatient service expansion. [source]
- Legal outcomes from ongoing 340B-related court cases. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.